Methods of and pharmaceutical compositions for improving implantation of embryos

• US 20020088019A1
• Filed: 10/17/2001
• Published: 07/04/2002
• Est. Priority Date: 09/02/1997
• Status: Abandoned Application

• Current Assignee: Insight Strategy & Marketing Ltd.
• Original Assignee: Insight Strategy & Marketing Ltd.
• Inventors: Yacoby-Zeevi, Oron
• Application Number:
  US09/978,297
• Publication Number:
  US 20020088019A1
• Time in Patent Office: Days
• US Class Current: 800/21
• CPC Class Codes: A01K 67/0271 Chimeric vertebrates, e.g. comprising exogenous cells
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/54 Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61M 15/009 using medicine packages with incorporated spraying means, e.g. aerosol cans pocket atomiser of the injector type A61M11/08
• CPC Class Codes: C12N 9/2402 hydrolysing O- and S- glycosyl compounds (3.2.1)
• CPC Class Codes: C12Y 302/01128 Glycyrrhizinate beta-glucuronidase (3.2.1.128), i.e. GL beta-D-glucoronidase
• CPC Class Codes: C12Y 302/01166 Heparanase (3.2.1.166)
• CPC Class Codes: G06F 18/24323 Tree-organised classifiers

Abstract

Methods of improving embryo implantation are disclosed and comprise contacting a receptive uterus and/or an embryo with an effective amount of heparanase and implanting the embryo in the receptive uterus.

Claims

1. A method of improving embryo implantation, the method comprising contacting an embryo with an effective amount of heparanase and implanting the embryo in a receptive uterus.

2. The method of claim 1, wherein said heparanase is a mature heparanase.

3. The method of claim 1, wherein said heparanase is a pro-heparanase, cleavable into mature heparanase.

4. The method of claim 1, wherein contacting the embryo with an effective amount of heparanase is in vitro.

5. The method of claim 1, wherein contacting the embryo with an effective amount of heparanase is in utero.

6. The method of claim 1, wherein the embryo is generated in vitro via in vitro fertilization.

7. A method of improving embryo implantation, the method comprising contacting a receptive uterus with an effective amount of heparanase and implanting the embryo in the receptive uterus.

8. The method of claim 7, wherein said heparanase is a mature heparanase.

9. The method of claim 7, wherein said heparanase is a pro-heparanase, cleavable into mature heparanase.

10. The method of claim 7, wherein the embryo is generated in vitro via in vitro fertilization.

11. The method of claim 7, wherein contacting the receptive uterus with the effective amount of heparanase precedes implanting the embryo in the receptive uterus.

12. The method of claim 7, wherein contacting the receptive uterus with the effective amount of heparanase is concurrent to implanting the embryo in the receptive uterus.

14. The method of claim 13, wherein said heparanase is a mature heparanase.

15. The method of claim 13, wherein said heparanase is a pro-heparanase, cleavable into mature heparanase.

16. The method of claim 13, wherein contacting the embryo with an effective amount of heparanase is in vitro.

17. The method of claim 13, wherein contacting the embryo with an effective amount of heparanase is in utero.

18. The method of claim 13, wherein the embryo is generated in vitro via in vitro fertilization.

19. The method of claim 13, wherein contacting the receptive uterus with the effective amount of heparanase precedes implanting the embryo in the receptive uterus.

20. The method of claim 13, wherein contacting the receptive uterus with the effective amount of heparanase is concurrent to implanting the embryo in the receptive uterus.

13. A method of improving embryo implantation, the method comprising contacting a receptive uterus with an effective amount of heparanase, contacting an embryo with an effective amount of heparanase and implanting the embryo in the receptive uterus.

21. A method of improving IVF embryo implantation, the method comprising contacting an IVF embryo with an effective amount of heparanase and implanting the embryo in a receptive uterus.

22. The method of claim 21, wherein said heparanase is a mature heparanase.

23. The method of claim 21, wherein said heparanase is a pro-heparanase, cleavable into mature heparanase.

24. The method of claim 21, wherein contacting the IVF embryo with an effective amount of heparanase is in vitro.

25. The method of claim 21, wherein contacting the IVF embryo with an effective amount of heparanase is in utero.

27. The method of claim 26, wherein said heparanase is a mature heparanase.

28. The method of claim 26, wherein said heparanase is a pro-heparanase, cleavable into mature heparanase.

29. The method of claim 26, wherein contacting the receptive uterus with the effective amount of heparanase precedes implanting the IVF embryo in the receptive uterus.

30. The method of claim 26, wherein contacting the receptive uterus with the effective amount of heparanase is concurrent to implanting the IVF embryo in the receptive uterus.

26. A method of improving IVF embryo implantation, the method comprising contacting a receptive uterus with an effective amount of heparanase and implanting the IVF embryo in the receptive uterus.

31. A method of improving IVF embryo implantation, the method comprising contacting a receptive uterus with an effective amount of heparanase, contacting an IVF embryo with an effective amount of heparanase and implanting the IVF embryo in the receptive uterus.

32. The method of claim 31, wherein said heparanase is a mature heparanase.

33. The method of claim 31, wherein said heparanase is a pro-heparanase, cleavable into mature heparanase.

34. The method of claim 31, wherein contacting the IVF embryo with an effective amount of heparanase is in vitro.

35. The method of claim 31, wherein contacting the IVF embryo with an effective amount of heparanase is in utero.

36. The method of claim 31, wherein contacting the receptive uterus with the effective amount of heparanase precedes implanting the IVF embryo in the receptive uterus.

37. The method of claim 31, wherein contacting the receptive uterus with the effective amount of heparanase is concurrent to implanting the IVF embryo in the receptive uterus.

39. The embryo of claim 38, wherein said heparanase is a mature heparanase.

40. The embryo of claim 38, wherein said heparanase is a pro-heparanase, cleavable into mature heparanase.

41. The embryo of claim 38, between 2 cells and a blastocyst.

38. An embryo coated with exogenous heparanase.

42. A pharmaceutical composition comprising, as an active ingredient, an effective amount of heparanase, the pharmaceutical composition is designed for intra-uterine application.

43. The pharmaceutical composition of claim 42, wherein said heparanase is a mature heparanase.

44. The pharmaceutical composition of claim 42, wherein said heparanase is a pro-heparanase, cleavable into mature heparanase.

46. The pharmaceutical composition of claim 45, wherein said heparanase is a mature heparanase.

47. The pharmaceutical composition of claim 45, wherein said heparanase is a pro-heparanase, cleavable into mature heparanase.

49. The embryo growth composition of claim 48, wherein said heparanase is a mature heparanase.

50. The embryo growth composition of claim 48, wherein said heparanase is a pro-heparanase, cleavable into mature heparanase.

45. A pharmaceutical composition comprising, as an active ingredient, an effective amount of heparanase, the pharmaceutical composition is designed for application to an embryo in vitro.

48. An embryo growth composition comprising an effective amount of nutrients for embryonic growth and an effective amount of heparanase for assisting in embryo implantation.